

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

**BIOFRONTERA INCORPORATED,
BIOFRONTERA BIOSCIENCE GMBH,
BIOFRONTERA PHARMA GMBH,**

AND

BIOFRONTERA AG

Petitioners

v.

DUSA PHARMACEUTICALS, INC.

Patent Owner

PATENT 10,357,567

DECLARATION OF HOWARD ROGERS, MD, PHD

Biofrontera Exhibit 1003
Biofrontera Inc. et al. v. DUSA Pharmaceuticals, Inc.
IPR2022-00056

TABLE OF CONTENTS

I.	Education and Experience	1
II.	Compensation	3
III.	Legal Considerations	4
	A. Anticipation	4
	B. Obviousness.....	5
	C. Claim Construction	8
IV.	Level of Ordinary Skill in the Art	9
V.	Task Summary	10
VI.	State of the Art.....	14
	A. 5-Aminolevulinic Acid (ALA) Photodynamic Therapy	14
	B. Light Sources Utilized in ALA PDT.....	18
	C. Treating Actinic Keratosis using PDT	23
	D. Occlusion with plastic wrap to minimize transepidermal water loss and enhance penetration of ALA was well known	26
	E. State of the Art Summary.....	30
VII.	The '567 Patent.....	32
	A. The '567 Patent Description and Claims	32
	B. '567 Patent Application (U.S. Patent Application No. 15/869,164)...	42
VIII.	Claim Construction.....	47
IX.	Application of the Prior Art to the Challenged Claims	48
	A. Ground 1: Claims 1-4 and 6-10 Are Taught by Willey	49
	1. Claim 1	50
	2. Claim 1a	51
	3. Claim 1b	52
	4. Claim 1c	54
	5. Claim 2	57
	6. Claim 3	58
	7. Claim 4	61
	8. Claim 4a	61

9.	Claim 4b	61
10.	Claim 4c	62
11.	Claim 6 / Claim 7	62
12.	Claim 8	64
13.	Claim 8a	65
14.	Claim 8b	66
15.	Claim 8c	67
16.	Claim 8d	70
17.	Claim 9	70
18.	Claim 10	72
B.	Ground 2 – Claim 3 Is Met by the Combination of Willey with Ameluz	73
1.	Claim 3	74
C.	Ground 3 – Claim 5 Is Met by the Combination of Willey with Sotiriou	79
2.	Claim 5	81
D.	Ground 4: Claims 1-9 Are Taught by Noven Pharma	84
1.	Claim 1	85
2.	Claim 1a	87
3.	Claim 1b	88
4.	Claim 1c	90
5.	Claim 2	92
6.	Claim 3	95
7.	Claim 4	99
8.	Claim 4a	99
9.	Claim 4b	100
10.	Claim 4c	100
11.	Claim 5	101
12.	Claim 6 / Claim 7	103
13.	Claim 8	105
14.	Claim 8a	106

15.	Claim 8b	108
16.	Claim 8c	109
17.	Claim 8d	110
18.	Claim 9	110
E.	Ground 5 – Claim 3 Is Met by the Combination of Noven Pharma and Fauteck	112
3.	Claim 3	114
F.	Ground 6 – Claim 10 Is Met by the Combination of Noven Pharma with the BLU-U Operating Manual	117
2.	Claim 10	119
X.	Claim Charts	122
A.	Ground 1: Claims 1-4 and 6-10 are taught by Willey	122
B.	Ground 2: Claim 3 is met by the combination of Willey with Ameluz	131
C.	Ground 3: Claim 5 is met by the combination of Willey with Sotiriou	134
D.	Ground 4: Claims 1-9 are taught by Noven Pharma	135
E.	Ground 5: Claim 3 is met by the combination of Noven Pharma with Fauteck.	149
F.	Ground 6: Claim 10 is met by the combination of Noven Pharma with the BLU-U operating manual	152
XI.	Additional Remarks	152

DECLARATION OF DR. HOWARD ROGERS

1. I, Howard Rogers, declare as follows:

2. My name is Howard Rogers. I am over the age of twenty-one (21) years, of sound mind, and capable of making the statements set forth in this Declaration. I am competent to testify about the matters set forth herein. All the facts and statements contained herein are within my personal knowledge and they are, in all things, true and correct.

3. I have been asked by Biofrontera Incorporated, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (collectively, “Biofrontera”) to submit this declaration in support of their challenge to the validity of all claims of U.S. Patent No. 10,357,567 (“the ‘567 patent”).

I. Education and Experience

4. My *curriculum vita* is attached as Exhibit 1004.

5. I am a board-certified dermatologist and a fellowship-trained Mohs micrographic surgeon. I received a Bachelor of Science degree in Biology from Harvard University in 1989, where I graduated magna cum laude. My undergraduate thesis research focused on the immunological response of mast cells. I attended medical school at Washington University School of Medicine in St. Louis from 1989-1996. I graduated with honors, with both an M.D. and a Ph.D. My Ph.D. thesis involved seminal research into mechanisms of infectious immunity. At graduation,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.